Skip to main content

Chromos Molecular Systems and Pfizer, Cell Signaling Technology and Chiron, NCI and GeneGo, and Qiagen and NCI

Premium

Chromos Licenses Cellular Engineering Tech to Pfizer

Chromos Molecular Systems said last week that it will non-exclusively license to Pfizer its ACE System to develop cell lines for research, development, and manufacturing of Pfizer products.

The licensing agreement expands upon an original agreement announced in December, under which Chromos is using the ACE System to engineer cell lines to express a Pfizer protein. Pfizer will continue to support this work, Chromos said.

Financial terms of the deal were not disclosed.


Cell Signaling Technology and Chiron Conduct Joint Study

Cell Signaling Technology said last week that it has reached an agreement with Chiron to perform a pilot study using CST's PhosphoScan technology to identify phosphorylation sites and prospective biomarkers of protein tyrosine kinase targets.

Further terms of the agreement were not disclosed.


NCI Licenses GeneGo's Pathway Analysis Software

GeneGo has licensed its pathway analysis software to the National Cancer Institute, the St. Joseph, Mich.-based company said last week.

Under the agreement, all NCI researchers have access to the 2.5 version of GeneGo's MetaCore software through their web browsers, GeneGo said.


Qiagen and NCI to Develop siRNAs for Cancer Research

Qiagen and the National Cancer Institute will co-develop and validate a set of siRNAs for cancer genes for use by NCI researchers, Qiagen said last week.

The validated siRNA set will be made available to the general research community following the characterization project, Qiagen said.

Financial terms of the deal were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.